Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32results about How to "Minimal fluctuation" patented technology

Combined cryogenic distillation and PSA for argon production

ActiveUS20070209508A1Improve processingImprovements in the refining of crude argonSolidificationGas treatmentChemistryGetter
A method and apparatus for producing high purity argon by combined cryogenic distillation and adsorption technologies is disclosed. Crude argon from a distillation column or a so-called argon column is passed to a system of adsorption vessels for further purification. Depressurization gas from adsorption is introduced back, in a controlled manner, to the distillation column and / or a compressor or other means for increasing pressure. Particulate filtration and getter purification may optionally be used.
Owner:AIR PROD & CHEM INC

Blasting agent and blasting method

A system including at least one means for mechanical processing of surfaces, in particular steel or cast iron beads using a blasting agent (5). An additive (6) for degreasing and cleaning of the surface to be blasted (2) and / or of the blasting agent is provided with the blasting agent (5), and comprising a granular material (6), which exhibits a lower breaking strength under the mechanical stresses that the blasting agent (5) is subject to during the blasting procedure than the at least one means for mechanical processing of the surfaces themselves. As the granular material (6) breaks down, additional additive (6) is added into the blasting agent (5) such that the proportion of the additive (6) in the blasting agent mixture blend (5) remains largely generally constant even at a prolonged operation of the device.
Owner:KOMPOFERM

Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus

InactiveUS7217730B2Treatment or prevention of Hepatitis C viral infectionAvoid absorptionBiocideOrganic chemistryMammalHepatitis C virus
The invention is directed to methods of treating, preventing, or inhibiting a Hepatitis C viral infection in a mammal comprising contacting the mammal with an effective amount of a compound of the formula:Wherein substitutions at R1, R2, R3—R12, and Y are set forth in the specification.
Owner:WYETH +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products